Role of the kidneys in resistant hypertension

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Khawaja, Z ^a   Wilcox, C S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; CYCLOSPORIN; DARUSENTAN; DIURETIC AGENT; FLUDROCORTISONE; GLUCOCORTICOID; METOLAZONE; MINERALOCORTICOID ANTAGONIST; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DIURESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; EXTRACELLULAR SPACE; FLUID RETENTION; HORMONE RESPONSE; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LIFESTYLE MODIFICATION; NATRIURESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SALT INTAKE; SIDE EFFECT; SLEEP DISORDERED BREATHING; SODIUM DEPLETION; SODIUM RESTRICTION; SODIUM RETENTION; VASOCONSTRICTION; WATER RETENTION;

EID: 84855291158     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/143471     Document Type: Review

References (64)

1. Genovese G., Friedman D. J., Ross M. D., Lecordier L., Uzureau P., Freedman B. I., Bowden D. W., Langefeld C. D., Oleksyk T. K., Uscinski Knob A. L., Bernhardy A. J., Hicks P. J., Nelson G. W., Vanhollebeke B., Winkler C. A., Kopp J. B., Pays E., epays@ulb.ac.be Pollak M. R., mpollak@bidmc.harvard.edu Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010 329 5993 841 845 10.1126/science.1193032
2. Guyton A. C., Manning R. D. Jr., Hall J. E., Norman R. A. Jr., Young D. B., Pan Y. J., The pathogenic role of the kidney. Journal of Cardiovascular Pharmacology 1984 6 supplement 1 S151 S161 (Pubitemid 14123983)
3. Koomans H. A., Roos J. C., Boer P., Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982 4 2 190 197 2-s2.0-0020053596 (Pubitemid 12162017)
4. Gaddam K. K., Nishizaka M. K., Pratt-Ubunama M. N., Pimenta E., Aban I., Oparil S., Calhoun D. A., Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Archives of Internal Medicine 2008 168 11 1159 1164 2-s2.0-45149100695 10.1001/archinte.168.11.1159 (Pubitemid 351831398)
5. Brater D. C., Anti-inflammatory agents and renal function. Seminars in Arthritis and Rheumatism 2002 32 3 33 42 2-s2.0-0036933008 10.1053/sarh.2002. 37216 (Pubitemid 36055619)
6. Goldblatt H., Studies on experimental hypertension. Annals of Internal Medicine 1937 11 69
7. Brunner H. R., Kirshman J. D., Sealey J. E., Laragh J. H., Hypertension of renal origin: evidence for two different mechanisms. Science 1971 174 4016 1344 1346 2-s2.0-0015238912
8. Granger J. P., Schnackenberg C. G., Renal mechanisms of angiotensin II-induced hypertension. Seminars in Nephrology 2000 20 5 417 425 2-s2.0-0033821585
9. Wheatley K., Ives N., Gray R., Kalra P. A., Moss J. G., Baigent C., Carr S., Chalmers N., Eadington D., Hamilton G., Lipkin G., Nicholson A., Scoble J., Revascularization versus medical therapy for renal-artery stenosis. New England Journal of Medicine 2009 361 20 1953 1962 2-s2.0-70449650655 10.1056/NEJMoa0905368
10. Van Jaarsveld B. C., Derkx F. H. M., Krijnen P., Pieterman H., Man In't Veld A. J., Woittiez A. J. J., Dees A., Postma C. T., Schalekamp M. A. D. H., Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study. Contributions to Nephrology 1996 119 54 58 2-s2.0-0029691412
11. Bax L., Woittiez A. J. J., Kouwenberg H. J., Mali W. P. T. M., Buskens E., Beek F. J. A., Braam B., Huysmans F. T. M., Schultze Kool L. J., Rutten M. J. C. M., Doorenbos C. J., Aarts J. C. N. M., Rabelink T. J., Plouin P. F., Raynaud A., Van Montfrans G. A., Reekers J. A., Van Den Meiracker A. H., Pattynama P. M. T., Van De Ven P. J. G., Vroegindeweij D., Kroon A. A., De Haan M. W., Postma C. T., Beutler J. J., Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Annals of Internal Medicine 2009 150 12 840 848 2-s2.0-67449089069
12. Murphy T. P., Cooper C. J., Dworkin L. D., Henrich W. L., Rundback J. H., Matsumoto A. H., Jamerson K. A., D'Agostino R. B., The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. Journal of Vascular and Interventional Radiology 2005 16 10 1295 1300 2-s2.0-26844522278 10.1097/01.RVI.0000176301.69756.28 (Pubitemid 41463986)
13. Marcantoni C., Zanoli L., Rastelli S., Tripepi G., Matalone M., Di Landro D., Scandura S., Tamburino C., Zoccali C., Castellino P., Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology 2009 22 1 13 16 2-s2.0-66349099443
14. Bloch M. J., Trost D. W., Pickering T. G., Sos T. A., August P., Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. American Journal of Hypertension 1999 12 1, part 1 1 7 2-s2.0-0033049625 10.1016/S0895-7061(98)00201-5 (Pubitemid 29118222)
15. DiBona G. F., Esler M., Translational medicine: the antihypertensive effect of renal denervation. American Journal of Physiology 2010 298 2 R245 R253 2-s2.0-75449083560 10.1152/ajpregu.00647.2009
16. Kopp U. C., Smith L. A., DiBona G. F., Renorenal reflexes: neural components of ipsilateral and contralateral renal responses. The American Journal of Physiology 1985 249 4 F507 F517 2-s2.0-17544391907 (Pubitemid 16185882)
17. Converse R. L., Jacobsen T. N., Toto R. D., Jost C. M. T., Cosentino F., Fouad- Tarazi F., Victor R. G., Sympathetic overactivity in patients with chronic renal failure. New England Journal of Medicine 1992 327 27 1912 1918 2-s2.0-0027075024 (Pubitemid 23006966)
18. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3
19. Esler M. D., Krum H., Sobotka P. A., Schlaich M. P., Schmieder R. E., Böhm M., Mahfoud F., Sievert H., Wunderlich N., Rump L. C., Vonend O., Uder M., Lobo M., Caulfield M., Erglis A., Azizi M., Sapoval M., Thambar S., Persu A., Renkin J., Schunkert H., Weil J., Hoppe U. C., Walton T., Scheinert D., Binder T., Januszewicz A., Witkowski A., Ruilope L. M., Whitbourn R., Bruck H., Downes M., Lüscher T. F., Jardine A. G., Webster M. W., Zeller T., Sadowski J., Bartus K., Straley C. A., Barman N. C., Lee D. P., Witteles R. M., Bhalla V., Massaro J. M., Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet 2010 376 9756 1903 1909 10.1016/S0140-6736(10) 62039-9
20. Zatz R., Baylis C., Chronic nitric oxide inhibition model six years on. Hypertension 1998 32 6 958 964 2-s2.0-0032406782 (Pubitemid 29001420)
21. Wang D., Iversen J., Wilcox C. S., Strandgaard S., Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney International 2003 64 4 1381 1388 2-s2.0-0141786849 10.1046/j.1523-1755.2003.00236.x (Pubitemid 37153804)
22. Modlinger P. S., Wilcox C. S., wilcoxch@georgetown.edu Aslam S., Nitric oxide, oxidative stress, and progression of chronic renal failure. Seminars in Nephrology 2004 24 4 354 365 10.1016/j.semnephrol.2004.04.007 (Pubitemid 38900635)
23. Wang D., Strandgaard S., Iversen J., Wilcox C. S., Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. American Journal of Physiology 2009 296 2 R195 R200 2-s2.0-61949358942 10.1152/ajpregu.90506.2008
24. Welch W. J., Tojo A., Wilcox C. S., Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. American Journal of Physiology 2000 278 5 F769 F776 2-s2.0-0034034151 (Pubitemid 30351078)
25. Wang D., Chabrashvili T., Wilcox C. S., Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circulation Research 2004 94 11 1436 1442 2-s2.0-2942711439 10.1161/01.RES.0000129578.76799.75 (Pubitemid 38786447)
26. Wilcox C. S., Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? American Journal of Physiology 2005 289 4 R913 R935 2-s2.0-25844513144 10.1152/ajpregu.00250.2005 (Pubitemid 41397037)
27. Oliver J. J., Dear J. W., Webb D. J., Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010 56 1 62 67 2-s2.0-77953807828 10.1161/HYPERTENSIONAHA.109.147686
28. Johnson A. G., Nguyen T. V., Day R. O., Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Annals of Internal Medicine 1994 121 4 289 300 2-s2.0-0028580588
29. Bakris G. L., Kern S. R., Renal dysfunction resulting from NSAIDs. American Family Physician 1989 40 4 199 204 2-s2.0-0024453974 (Pubitemid 19260720)
30. Whelton A., White W. B., Bello A. E., Effects of celecoxib and rofecoxib on blood pressure and edema in patients more than or equal to 65 years of age with systemic hypertension and osteoarthritis. American Journal of Cardiology 2002 90 959 963 (Pubitemid 35232619)
31. Schimmer Bernard P., Parker Keith L., Brunton L. L., Lazo J. S., Parker K. L., Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005 chapter 59
32. Walker B. R., Edwards C. R. W., Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinology and Metabolism Clinics of North America 1994 23 2 359 377 2-s2.0-0028221461 (Pubitemid 24191810)
33. Wilcox C. S., Deng X., Doll A. H., Snellen H., Welch W. J., Nitric oxide mediates renal vasodilatation during erythropoietin-induced polycythemia. Kidney International 1993 44 2 430 435 2-s2.0-0027169342 (Pubitemid 23228700)
34. Krapf R., Hulter H. N., Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clinical Journal of the American Society of Nephrology 2009 4 2 470 480 2-s2.0-66849138375 10.2215/CJN.05040908
35. Robert N., Wong G. W., Wright J. M., Effect of cyclosporine on blood pressure. Cochrane Database of Systematic Reviews 2010 1 CD007893 2-s2.0-77950911605
36. Braith R. W., Mills R. M. Jr., Wilcox C. S., Davis G. L., Wood C. E., Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. Journal of the American College of Cardiology 1996 27 2 375 383 2-s2.0-0030063007 10.1016/0735-1097(95)00467-X (Pubitemid 26045504)
37. Ruggenenti P., Perico N., Mosconi L., Gaspari F., Benigni A., Amuchastegui C. S., Bruzzi I., Remuzzi G., Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney International 1993 43 3 706 711 2-s2.0-0027412441 (Pubitemid 23071956)
38. Pesavento T. E., Jones P. A., Julian B. A., Curtis J. J., Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. Journal of the American Society of Nephrology 1996 7 6 831 835 2-s2.0-0030377076 (Pubitemid 27465975)
39. Chapman N., neil.chapman@st-marys.nhs.uk Dobson J., Wilson S., Dahlöf B., Sever P. S., Wedel H., Poulter N. R., Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 49 4 839 845 10.1161/01.HYP.0000259805.18468.8c (Pubitemid 351664214)
40. Nishizaka M. K., Zaman M. A., Calhoun D. A., Efficacy of lowdose spironolactone in subjects with resistant hypertension. American Journal of Hypertension 2003 16 11 925 930 2-s2.0-0142231538 10.1016/S0895-7061(03)01032-X (Pubitemid 37315491)
41. Gross E., Rothstein M., Dombek S., Juknis H. I., Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. American Journal of Kidney Diseases 2005 46 1 94 101 2-s2.0-20544445158 10.1053/j.ajkd.2005.03.005 (Pubitemid 40848437)
42. Messerli F. H., Vasodilatory edema: a common side effect of antihypertensive therapy. Current Cardiology Reports 2002 4 6 479 482 2-s2.0-0036831248
43. Grassi G., Facchini A., Trevano F. Q., Dell'Oro R., Arenare F., Tana F., Bolla G., Monzani A., Robuschi M., Mancia G., Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005 46 2 321 325 2-s2.0-23244437764 10.1161/01.HYP.0000174243.39897.6c (Pubitemid 41099164)
44. Lavie L., Hefetz A., Luboshitzky R., Lavie P., Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. Journal of Molecular Neuroscience 2003 21 1 57 63 2-s2.0-0141450467 10.1385/JMN:21:1:57 (Pubitemid 37204873)
45. Gaddam K., Pimenta E., Thomas S. J., Cofield S. S., Oparil S., Harding S. M., Calhoun D. A., Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension 2009 24 532 537 2-s2.0-72049115551 10.1038/jhh.2009.96
46. Saito Y., Nakao K., Mukoyama M., Imura H., Increased plasma endothelin level in patients with essential hypertension. New England Journal of Medicine 1990 322 3 205 2-s2.0-0025057374 (Pubitemid 20036412)
47. Weber M. A., Black H., Bakris G., Krum H., Linas S., Weiss R., Linseman J. V., Wiens B. L., Warren M. S., Lindholm L. H., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. The Lancet 2009 374 9699 1423 1431 2-s2.0-70350133404 10.1016/S0140-6736(09)61500-2
48. Bakris G. L., gbakris@gmail.com Lindholm L. H., Black H. R., Krum H., Linas S., Linseman J. V., Arterburn S., Sager P., Weber M., Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010 56 5 824 830 10.1161/HYPERTENSIONAHA.110. 156976
49. He F. J., MacGregor G. A., Effect of longer-term modest salt reduction on blood pressure. Cochrane Database of Systematic Reviews 2004 3 CD004937 2-s2.0-16544378384
50. Nishizaka M. K., Pratt-Ubunama M., Zaman M. A., Cofield S., Calhoun D. A., Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. American Journal of Hypertension 2005 18 6 805 812 2-s2.0-19744368451 10.1016/j.amjhyper.2005.01.002 (Pubitemid 40745266)
51. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
52. Pimenta E., Gaddam K. K., Oparil S., Aban I., Husain S., Dell'Italia L. J., Calhoun D. A., Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009 54 3 475 481 2-s2.0-70349249634 10.1161/HYPERTENSIONAHA.109. 131235
53. Ellison D., Wilcox C. S., Brenner B., Diuretics. The Kidney 2008 8th Philadelphia, Pa, USA Saunders and Elsevier 1648 1678
54. Khosla N., Chua D. Y., Elliott W. J., Bakris G. L., Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? Journal of Clinical Hypertension 2005 7 6 354 356 2-s2.0-27744579877
55. Ernst M. E., Carter B. L., Goerdt C. J., Steffensmeier J. J. G., Phillips B. B., Zimmerman M. B., Bergus G. R., Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006 47 3 352 358 2-s2.0-33644981542 10.1161/01.HYP.0000203309. 07140.d3 (Pubitemid 43740274)
56. Loon N. R., Wilcox C. S., Unwin R. J., Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney International 1989 36 4 682 689 2-s2.0-0024455680 (Pubitemid 19239561)
57. Voelker J. R. Jr., Cartwright-Brown D., Anderson S., Leinfelder J., Sica D. A., Kokko J. P., Brater D. C., Comparison of loop diuresis in patients with chronic renal insufficiency. Kidney International 1987 32 4 572 578 2-s2.0-0023521927 (Pubitemid 17154747)
58. Wilcox C. S., Metabolic and adverse effects of diuretics. Seminars in Nephrology 1999 19 6 557 568 2-s2.0-0032745958 (Pubitemid 29518110)
59. Wilcox C. S., Mitch W. E., Kelly R. A., Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. Journal of Laboratory and Clinical Medicine 1983 102 3 450 458 2-s2.0-0020551162 (Pubitemid 13009620)
60. Wollam G. L., Tarazi R. C., Bravo E. L., Dustan H. P., Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. American Journal of Medicine 1982 72 6 929 938 2-s2.0-0019996229 (Pubitemid 12086597)
61. Fliser D., Schröter M., Neubeck M., Ritz E., Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney International 1994 46 2 482 488 2-s2.0-0028100623 (Pubitemid 24253057)
62. Ouzan J., Pérault C., Lincoff A. M., Carré E., Mertes M., The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension 2002 15 4 333 339 2-s2.0-0036110762 10.1016/S0895-7061(01)02342-1 (Pubitemid 34408973)
63. Houston M. C., Johnston P. E., Essential hypertension: new insights and controversies in treatment with diuretics. Southern Medical Journal 1986 79 8 984 990 2-s2.0-0022763540
64. Hood S. J., Taylor K. P., Ashby M. J., Brown M. J., The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007 116 3 268 275 2-s2.0-34547559617 10.1161/CIRCULATIONAHA.107. 690396 (Pubitemid 47196562)